You are here

  • Home
  • Archive
  • Volume 8, Issue 4
  • Single dose mifepristone, single dose levonorgestrel, or 2 dose levonorgestrel were effective emergency contraceptives

Article Text

Article menu
Download PDFPDF
Therapeutics
Single dose mifepristone, single dose levonorgestrel, or 2 dose levonorgestrel were effective emergency contraceptives

https://doi.org/10.1136/ebm.8.4.119

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 360, 1803. von Hertzen H, Piaggio G, Ding J, et al.. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.. ;. :. –10.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In women requesting emergency contraception, what is the relative effectiveness of a single dose of mifepristone, a single dose of levonorgestrel, or 2 separate doses of levonorgestrel in emergency contraception?

    Design

    Randomised (allocation concealed*), blinded (clinicians, patients, monitoring committee, {data collectors, outcome assesors, and data analysts}†),* controlled trial with 6 weeks of follow up.

    Setting

    15 family planning clinics in China, Finland, Georgia, Hungary, India, Mongolia, Slovenia, Sweden, Switzerland, and the UK.

    Patients

    4136 women (mean age 27 y) who presented for emergency contraception within 120 hours of 1 act of unprotected coitus in their present menstrual cycle. Women had to be healthy, have regular (24–42 d duration) menstrual cycles, and be willing to abstain from unprotected intercourse during the menstrual cycle. Women who had been pregnant or had recently discontinued hormonal contraception had to have had ≥1 complete and normal menstrual cycle before the current cycle. Exclusion criteria …

    View Full Text

    Footnotes

    • Source of funding: UNDP/UNFPA/ WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction.

    • For correspondence: Dr H von Hertzen, World Health Organization, Geneva, Switzerland. vonhertzenh{at}who.int

    • ↵* See glossary.

    • ↵† Information provided by author.